The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

S&P 500 (SNPINDEX: ^GSPC) up by nearly 30% year to date as of Dec. 11. However, not all stocks have performed nearly this ...

Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Shares of Moderna Inc. MRNA slipped 9.07% to $41.51 Tuesday, on what proved to be an all-around grim trading session for the ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

WASHINGTON (AP) — Biden conmuta unas 1.500 condenas y concede 39 indultos en un récord de indultos en la historia moderna de EEUU.

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.